Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stomach and colorectal cancer: Identifying patients who are suitable for immunotherapy

04.06.2019

Scientists from Uniklinik RWTH Aachen, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases Heidelberg (NCT) have developed an adaptive algorithm that can predict instability in microsatellites based directly on images of tissue samples.

Changes in certain sections of the genetic material of cancer cells, so-called microsatellites, can provide an important indication of whether immunotherapy may be successful in a patient with stomach or colorectal cancer.


Tissue from a patient (a) with microsatellite instability (MSI) and a patient (b) with microsatellite stability (MSS).

Photo credits: Jakob Nikolas Kather

Scientists from Uniklinik RWTH Aachen, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases Heidelberg (NCT) have developed an adaptive algorithm that can predict instability in microsatellites based directly on images of tissue samples.

This could help to potentially identify patients at an early stage who could benefit from immunotherapy. The research results were published in the journal Nature Medicine.

Only a small number of patients with stomach or colorectal cancer respond to immunotherapy. Some tumors lead to changes in the genetic material, and this can cause mutations in the sections of the genome, referred to as “microsatellites”, that are frequently replicated.

This microsatellite instability (MSI) is a characteristic for distinguishing between different cancers of the gastrointestinal tract and determines whether patients with these diseases are able to respond well to immunotherapy with checkpoint inhibitors. Detecting these properties usually requires a genetic or immunohistochemical test, which requires additional costs and is not always automatically performed for every patient in clinical practice.

The scientists in Aachen and Heidelberg, in collaboration with international colleagues, showed that a computer-aided adaptable algorithm, based on the concept of “deep learning”, enables MSI to be directly diagnosed based on routinely available images of tissue samples without the need for additional laboratory tests.

“With our approach, we have the potential to test any patient with colorectal cancer for MSI automatically and cost-effectively, which allows us to provide the option of immunotherapy to a larger group of colorectal cancer patients,” says Jakob Nikolas Kather, physician and scientist at the Clinic for Gastroenterology, Metabolic Diseases and Internal Intensive Care (Medical Clinic III) at Uniklinik RWTH Aachen and member of staff at DKFZ and NCT Heidelberg.“This makes it possible to identify patients who may otherwise never be considered for immunotherapy. However, this approach must be reviewed in prospective studies,” adds Dirk Jäger, Medical and Executive Director of the Department of Medical Oncology at NCT Heidelberg.

Immunotherapy for cancer

Cancer immunotherapies with so-called checkpoint inhibitors, which can be seen as active agents that release the “brakes” of the immune system, have attracted considerable attention in recent years. For colorectal cancer, however, checkpoint inhibitors have thus far only been successful in “microsatellite instable” tumors. In the more common “microsatellite stable” cases of colorectal cancer, checkpoint inhibitors have not shown objective response rates in previous studies. It remains challenging to predict which patients can benefit from immunotherapy in daily practice. This makes it all the more important to identify patients at an early stage who could benefit from immunotherapy in day-to-day clinical treatment.

Artificial intelligence in medicine

Artificial intelligence and adaptable algorithms are becoming increasingly prominent in medicine. Technological support has been required for a long time. The relevant data are entered into the applications, thereby training the algorithm to analyze large amounts of data and medical images to enable more efficient and more accurate treatments, such as the automatic detection of cancer cells.

Original publication
Jakob Nikolas Kather, Alexander T. Pearson, Niels Halama, Dirk Jäger, Jeremias Krause, Sven H. Loosen, Alexander Marx, Peter Boor, Frank Tacke, Ulf Peter Neumann,
Heike I. Grabsch, Takaki Yoshikawa, Hermann Brenner, Jenny Chang-Claude,
Michael Hoffmeister, Christian Trautwein, Tom Luedde (2019) Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, https://www.nature.com/articles/s41591-019-0462-y

An image for the press release is available free of charge on the internet:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/Meldungen/Bild...

Caption: Tissue from a patient (a) with microsatellite instability (MSI) and a patient (b) with microsatellite stability (MSS).

Notice for image material in press releases
The use of images is free of charge. The NCT Heidelberg permits one-time use in connection with coverage of the subject of the press release. Please list the photo credits: “Jakob Nikolas Kather”. The transmission of photographic material to third parties is only permitted after prior consultation with the NCT Press Office (Tel. 06221 56 5930, Email: friederike.fellenberg@nct-heidelberg.de). Use for commercial purposes is prohibited.

Press contact:
Dr. Friederike Fellenberg
National Center for Tumor Diseases Heidelberg (NCT)
Press and Public Relations
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
Email: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de

Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Communications and Marketing
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2843
Fax: +49 6221 42-2968
Email: s.kohlstaedt@dkfz.de
www.dkfz.de

Doris Rübsam-Brodkorb
Heidelberg University Hospital and Medical Faculty of the University of Heidelberg
Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
Email: doris.ruebsam-brodkorb@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de

Dr. Mathias Brandstädter
Leitung Unternehmenskommunikation
Uniklinik RWTH Aachen
Pauwelsstraße 30
52074 Aachen
Telefon: 0241 80-89893
Fax: 0241 80-3389893
mbrandstaedter@ukaachen.de

National Center for Tumor Diseases Heidelberg (NCT)
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital (UKHD) and German Cancer Aid. The NCT’s goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. This is true for both diagnosis and treatment, follow-up care or prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here, the patients benefit from an individual treatment plan prepared in interdisciplinary expert rounds, so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, the NCT Heidelberg has maintained a partner site in Dresden. The Hopp Children’s Cancer Center (KiTZ) was established in Heidelberg in 2017. The pediatric oncologists at KiTZ work together in parallel structures with the NCT Heidelberg.

German Cancer Research Center (DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.
The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Together with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic.
In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Heidelberg University Hospital
Heidelberg University Hospital (UKHD) is one of the most important medical centers in Germany; Heidelberg University’s Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 13,000 individuals and are involved in training and qualification. Every year approximately 65,000 patients are treated as inpatients and 56,000 as day patients in more than 50 specialized clinical departments with around 2,000 beds, with more than 1 million patients being treated as outpatients. Together with the German Cancer Research Center and German Cancer Aid, the Heidelberg University Hospital established The National Center for Tumor Diseases (NCT) Heidelberg as the leading oncology center of excellence in Germany. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present 3,700 aspiring physicians and doctors are studying in Heidelberg.

Uniklinik RWTH Aachen
The Uniklinik RWTH Aachen is a supramaximal care provider that combines patient-oriented medicine and nursing, teaching and research at an international level. With 36 specialist clinics, 25 institutes and five interdisciplinary units, the University Hospital covers the entire medical spectrum. Excellently qualified teams of doctors, nurses and scientists are competently committed to the health of the patients. The bundling of patient care, research and teaching in one central building offers the best conditions for intensive interdisciplinary exchange and close clinical and scientific networking. Around 7.000 employees provide patient-oriented medicine and care according to recognised quality standards. With 1.400 beds, the University Hospital treats around 50.000 inpatient and 200.000 outpatient cases per year.

Wissenschaftliche Ansprechpartner:

Jakob Nikolas Kather
Dirk Jäger

Originalpublikation:

Jakob Nikolas Kather, Alexander T. Pearson, Niels Halama, Dirk Jäger, Jeremias Krause, Sven H. Loosen, Alexander Marx, Peter Boor, Frank Tacke, Ulf Peter Neumann,
Heike I. Grabsch, Takaki Yoshikawa, Hermann Brenner, Jenny Chang-Claude,
Michael Hoffmeister, Christian Trautwein, Tom Luedde (2019) Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, https://www.nature.com/articles/s41591-019-0462-y

Weitere Informationen:

http://www.nature.com/articles/s41591-019-0462-y
http://www.nct-heidelberg.de

Dr. Friederike Fellenberg | idw - Informationsdienst Wissenschaft

Further reports about: CANCER Centrum für Tumorerkrankungen DKFZ MSI RWTH colorectal cancer immunotherapy

More articles from Life Sciences:

nachricht Too much of a good thing: overactive immune cells trigger inflammation
16.09.2019 | Universität Basel

nachricht The sleep neuron in threadworms is also a stop neuron
16.09.2019 | Goethe-Universität Frankfurt am Main

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tomorrow´s coolants of choice

Scientists assess the potential of magnetic-cooling materials

Later during this century, around 2060, a paradigm shift in global energy consumption is expected: we will spend more energy for cooling than for heating....

Im Focus: The working of a molecular string phone

Researchers from the Department of Atomically Resolved Dynamics of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg, the University of Potsdam (both in Germany) and the University of Toronto (Canada) have pieced together a detailed time-lapse movie revealing all the major steps during the catalytic cycle of an enzyme. Surprisingly, the communication between the protein units is accomplished via a water-network akin to a string telephone. This communication is aligned with a ‘breathing’ motion, that is the expansion and contraction of the protein.

This time-lapse sequence of structures reveals dynamic motions as a fundamental element in the molecular foundations of biology.

Im Focus: Milestones on the Way to the Nuclear Clock

Two research teams have succeeded simultaneously in measuring the long-sought Thorium nuclear transition, which enables extremely precise nuclear clocks. TU Wien (Vienna) is part of both teams.

If you want to build the most accurate clock in the world, you need something that "ticks" very fast and extremely precise. In an atomic clock, electrons are...

Im Focus: Graphene sets the stage for the next generation of THz astronomy detectors

Researchers from Chalmers University of Technology have demonstrated a detector made from graphene that could revolutionize the sensors used in next-generation space telescopes. The findings were recently published in the scientific journal Nature Astronomy.

Beyond superconductors, there are few materials that can fulfill the requirements needed for making ultra-sensitive and fast terahertz (THz) detectors for...

Im Focus: Physicists from Stuttgart prove the existence of a supersolid state of matte

A supersolid is a state of matter that can be described in simplified terms as being solid and liquid at the same time. In recent years, extensive efforts have been devoted to the detection of this exotic quantum matter. A research team led by Tilman Pfau and Tim Langen at the 5th Institute of Physics of the University of Stuttgart has succeeded in proving experimentally that the long-sought supersolid state of matter exists. The researchers report their results in Nature magazine.

In our everyday lives, we are familiar with matter existing in three different states: solid, liquid, or gas. However, if matter is cooled down to extremely...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Society 5.0: putting humans at the heart of digitalisation

10.09.2019 | Event News

Interspeech 2019 conference: Alexa and Siri in Graz

04.09.2019 | Event News

AI for Laser Technology Conference: optimizing the use of lasers with artificial intelligence

29.08.2019 | Event News

 
Latest News

Too much of a good thing: overactive immune cells trigger inflammation

16.09.2019 | Life Sciences

Scientists create a nanomaterial that is both twisted and untwisted at the same time

16.09.2019 | Materials Sciences

Researchers have identified areas of the retina that change in mild Alzheimer's disease

16.09.2019 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>